Académique Documents
Professionnel Documents
Culture Documents
Osama
diabetes
type one and type two
practical
2013
36
Diabetes
treatment
diabetes
treat
126
200
<<
Objective
Diabetes
fasting blood sugar
Hemoglobin A1C
glycated
6.2
diabetic
6.5
diabetes
controlled
fasting
Page |
126
130
90
It is recommended
fasting
180
post prandial
glycated hemoglobin
7
6
7
control
target
diabetes
type one
MODY
Page |
20
17
diabetes
category
type one
diabetes
type one
category
diabetes
MODY
Oral hypoglycemic
Oral hypoglycemic
controlled
MODY
Page |
positive
type one
oral hypoglycemic
response
respond
MODY
never << type one
respond
40
type two
family history
oral
30
C peptide
Investigations
type one
C peptide
<< type two
LADA
LADA
latent auto immune diabetes in adults
type one
auto immune
20
Page |
process
type one
late
oral hypoglycemic
type one
MODY
type two
oral hypoglycemic
0.8
0.3
60
aggressive
0.5
Page |
30 unit
NPH
crystalline << 40 %
mixed insulin
crystalline
1/3
intermediate
insulin
70 / 30 mixtard insulin
twice daily
30
dose
10
20
20
10
30
20
20
13 12
7
Page |
4 3
check
provided
emergency
Provided
500
type one
Insulin infusion
cold case
30
5 4
check
blood sugar
5 units
you cannot predict the response
30
35
5 4
stepwise
controlled
random
random
post prandial
controlled
post prandial
fasting
24
Page |
fasting
60
40
secretion
blood sugar
LANTUS
crystalline insulin
dose
Page |
40
15
30
type one
type two
45
LANTUS
LANTUS
dose
dose
LANTUS
say
30 %
45
LANTUS
15
LANTUS
peak
LANTUS
No Hypoglycemia at all
LANTUS
15
30
10 10 10
40 %
Page |
30 %
30 %
15
LANTUS
10 10 10
controlled
15
12 12
12
20
LANTUS
LANTUS
LANTUS
LANTUS
basal
sliding scale
sliding
sliding scale
LANTUS
basal
LANTUS
8
200
above
50
8
200
300
Page |
10
100
10
350
200
150
15
stable
10
15
stabilized
10
10
15
10
35
LANTUS
20
60
30
Page |
11
2/3
30
70 / 30 insulin mixtard
10
20
action
duration
crystalline insulin
8
NPH
16
dose
dose
NPH
peak
dose
controlled
Page |
12
Hypoglycemia
Mixtard
hypoglycemia
insulin analogue
rapidly acting
peak
insulin analogue
duration
Mixed
Mixed
Novo mix <<
70 / 30 ) Mixtard
mixed
Novo mix
Novo mix
dose
<<
insulin analogue
30 %
Mixtard
sorry
crystalline insulin
mixtard
crystalline insulin << 70 %
Novo mix
crystalline insulin
70 %
Page |
13
twice
insulin analogue
dose
mix
Overlap
Overlap
dose
duration
aggressive
aggressive
physiological
LANTUS
3 << crystalline insulin
crystalline
LANTUS
insulin
3
overlap
LANTUS
analogue
Insulin analogue
Novo rapid
crystalline insulin
short acting insulin analogue << Insulin
Novo rapid
crystalline insulin
Novo rapid
Mixtard
Page |
14
30 %
70 %
Mixtard
Novo mix
Novo mix
novo mix
analogue
Novo rapid
Hypoglycemia
Novo rapid
mixtard
Novo rapid
LANTUS
Insulin analogue
Long acting
LANTUS
errors
trial
Peak
20
15
60
60
<< LANTUS
3
divided
crystalline
novo rapid
Insulin analogue
LANTUS
12 15
Page |
15
10
LANTUS
200
50
sliding scale
150
50
170
200
50
5
<< traditional
<<
Hypoglycemia
dose
dose
Novo mix
insulin analogue
30 %
70 %
NPH
duration
16
insulin analogue
rapidly acting
short duration
Page |
16
updated
Novo rapid
Novo rapid
long acting
insulin analogue
LANTUS
LANTUS
short acting
Novo rapid
premixed
Novo mix
Novo rapid
APIDRA
Novo rapid
LANTUS
Long acting
short acting
Page |
17
novo mix
Novo rapid
40
25
40
hypoglycemia
stepwise
emergency
type two
release
Oral
Secretagogues
secretagogues
secretagogues
secretagogues
Amaryl
Diamicron
Page |
18
amaryl
amaryl
Amaryl
Sulphonylurea
<< secretagogue
release
exhaustion
release
Amaryl
on and off
On and off
release
Amaryl
On and off
One dose
Amaryl
One dose
Page |
19
diabetic
emergency
1
Amaryl
5 4
3 << Amaryl
type two
Obese
insulin resistance
1 << amaryl
2
3
8
Page |
20
Amaryl
dose
<< practically
6
3
3
Insulin sensitizer
Insulin sensitizer
Biguanides
500
1000
850
500
500
Amaryl
3
500
500
3
Page |
21
1000
1000
1000
3
Amaryl
Amaryl
Exhaustion
responding
no way << definitely type two
sort of insulin resistance
You must add insulin sensitizer
maximum dose of Amaryl
Off
3
insulin sensitizer
exhausted
Page |
22
Insulin action
to preserve
Diamicron
MR
80
Diamicron
MR
Modified release
40
Diamicron
3
Amaryl
amaryl
MR
Modified release
24
60
Modified release
Diamicron
30
30
60
90
120
one dose
one dose
Diamicron MR
30
One dose
two doses
better to be one dose
Page |
23
Amaryl
Diamicron MR
30
60
120
Insulin sensitizer
renal impairment
hepatic
COPD
Renal impairment
Kidney
renal impairment
excreted
lactic acidosis
diabetic
side effects
insulin sensitizer
Page |
24
Pioglitazones
Avandia
Glustin
X Cross
Avandia
Avandia
cardio-toxic
absolutely contraindicated
coronary heart disease
heart failure
heart disease
salt and water retention
pain
12 10
Avandia
Avandia
Glustin
30
15
Glustin
Glustin
heart failure
coronary
30
Page |
25
15
Glustin
Diamicron MR
Amaryl
Glustin
oral hypoglycemic
Amaryl
6
Diamicron
120
3
30
Oral hypoglycemic
1000
15
Glustin
insulin
Oral hypoglycemia
10
combination
2
48
12
Page |
26
shift
LANTUS
Oral
LANTUS
LANTUS
Oral
Amaryl
Amaryl
LANTUS
basal secretion
LANTUS
Amaryl
release
Amaryl
Novo norm
Novo Norm
normalized
0.5
Amaryl
Amaryl
<<
Novo norm
average
Novo norm
long acting << Amaryl
diet
Mainly
Amaryl
Novo norm
very short action
Novo norm
Page |
27
Novo norm
diet
basal insulin
LANTUS
Amaryl
Amaryl
Novo norm
Novo norm
LANTUS
Novo norm
LANTUS
LANTUS
satisfied
Exhausted
insulin
type one
dose
type one dose
0.8 0.3 << dose
Up to 2 units per kg
insulin resistance
type one
type two
resistance
Page |
28
type one
type two
dose
Mixtard
LANTUS
insulin sensitizer
type two
insulin resistance
incretin
incretin effect
incretins
Oral
intra venous
oral
IV
IV
Page |
29
Oral
oral
500
oral
glucagon related peptide
intestine
incretin effect
incretin effect
oral
IV
glucagon related peptide
release
glucagon related peptide
release
glucagon level
appetite
Page |
30
Oral
glucagon related peptide << intestine
glucagon related peptide
6
100
enhance
adjuvent therapy
sorry
effective
Page |
31
Amaryl
100
30
200
Novo rapid
Long acting << LANTUS
short acting
insulin insulin analogue
Hypoglycemia
overlap duration
Page |
32
Diabetes
55 12
2013
2
www.facebook.com/dr.tafreegh
Page |
33